---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-22-000117"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2022-10-20T23:59:59+00:00"
generated_at: "2026-06-23T02:24:45.041429+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Xeris reports positive Phase 1 data for SC levothyroxine (XP-8121); weekly dosing matches daily oral

## Summary
- Phase 1 study (n=60) shows proof-of-concept for once-weekly SC XP-8121 with steady-state exposure similar to daily oral Synthroid.
- Population PK model implies dose conversion factor of 4X: weekly 1200 μg SC equivalent to daily 300 μg PO levothyroxine.
- XP-8121 well tolerated at all doses (600, 1200, 1500 μg); safety profile comparable to Synthroid 600 μg PO.
- Company expects FDA End-of-Phase 1 meeting feedback by end of 2022.

## SEC filing metadata
- accession: 0001867096-22-000117
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2022-10-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709622000117/0001867096-22-000117-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709622000117/xers-20221020.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-22-000117
- JSON: https://secwatch.observer/filing/0001867096-22-000117.json
- Plain text: https://secwatch.observer/filing/0001867096-22-000117.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.